Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients with Septic Shock - PROWESS-SHOCK

• Register: EUCTR
• Last refreshed on: 15 May 2012
• Main ID: EUCTR2007-005441-38-IT
• Date of registration: 08/02/2008
• Prospective Registration: Yes
• Primary sponsor: ELI LILLY
• Public title: Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients with Septic Shock - PROWESS-SHOCK
• Scientific title: Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients with Septic Shock - PROWESS-SHOCK
• Date of first enrolment: 06/03/2008
• Target sample size: 1500
• Recruitment status: Not Recruiting
• URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2007-005441-38
• Study type: Interventional clinical trial of medicinal product
• Study design: Controlled: yes Randomised: yes Open: no Single blind: no Double blind: yes Parallel group: yes Cross over: no Other: no If controlled, specify comparator, Other Medicinial Product: no Placebo: yes Other: yes Other specify the comparator: - same IMP used at different dosage

Countries of recruitment

Belgium, Czech Republic, Finland, France, Germany, Italy, Netherlands, Portugal, Spain, United Kingdom

Key inclusion & exclusion criteria

Inclusion criteria:
[1] Must be an adult (≥18 years old) [2] Must have evidence of an infection for which the patient is receiving intravenous antimicrobial therapy (refer to Protocol Attachment EVDP.4 for guidelines). [3] Must have systemic inflammatory response syndrome (SIRS). Patients must meet at least 2 of the criteria defined below during the 36 hours prior to study entry. (a) Core temperature ≥38 C (100.4 F) or ≤36 C (96.8 F). Core temperature is defined as rectal, central catheter, or tympanic. If oral or axillary temperature is used, add 0.5 C or 1 F to the measured value. Hypothermia (≤36 C or 96.8 F) must be determined by a rectal or central catheter temperature. (b) Heart rate ≥90 beats/minute. (c) Respiratory rate ≥20 breaths per minute or a PaCO2 ≤32 mm Hg or mechanical ventilation for an acute process. (d) White blood cell count of ≥12,000/mm3 or ≤4000/mm3 or >10% immature neutrophils. [4] Must have septic shock, which is defined as the following: (a) The patient must have received ≥30 mL/kg of intravenous fluid during the resuscitation period. The resuscitation period begins 4 hours prior to the initiation of vasopressor therapy and ends 4 hours after start of vasopressor therapy). (b) The patient must have a continuous requirement for vasopressor support for at least 4 hours at a minimum dose of at least 1 of the vasopressors shown below: ◊ norepinephrine ≥5 mcg/min ◊ dopamine ≥10 mcg/kg/min ◊ phenylephrine ≥25 mcg/min ◊ epinephrine ≥5 mcg/min ◊ vasopressin ≥0.03 units/min (c) Must have clinical signs consistent with hypoperfusion. The patient must meet at least 1 of the following criteria during the 36 hours prior to study entry: ◊ Metabolic acidosis: base deficit ≥5.0 mEq/L or venous bicarbonate <18 mEq/L or lactate ≥2.5 mMol/L. ◊ Acute oliguria/renal injury: urine output <0.5 mL/kg/h for 1 hour or a 50% increase in creatinine from a known or calculated baseline level (estimated using the MDRD equation or a similar estimation of baseline creatinine, refer to Protocol Attachment EVDP.6). Patients with a history of chronic renal disease must meet the metabolic acidosis or acute hepatic dysfunction criterion. ◊ Acute hepatic dysfunction: AST or ALT >500 IU/dL or bilirubin >2 g/dL. Patients with a history of acute hepatitis or chronic liver disease must meet the metabolic acidosis or oliguria/renal injury criterion for evidence of hypoperfusion.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion criteria:
[6] Have receivedvasopressor therapy (at any dose) for greater than 24 hours prior to the start of study drug. [7] Have sepsis-induced organ dysfunction (respiratory, renal, hematologic, or unexplained metabolic acidosis; refer to Protocol Attachment EVDP.3 for definitions) for greater than 36 hours prior to the start of the study drug infusion. [8] Have single organ dysfunction and recent surgery (within 30 days of study entry). [9] Have had surgery performed within the 12-hour period immediately preceding the study drug infusion, or are postoperative with evidence of active bleeding, or have planned or anticipated surgery during the infusion period [10] Have a platelet count <30,000/mm3. [11] Have a prothrombin time-international normalized ratio (INR) >5.0. [12] Have active internal bleeding or are at increased risk for bleeding, [13] Are receiving any of the following medications at study entry or will have a concurrent need for any of the following medications during the study drug infusion: (a) Therapeutic heparin, defined as unfractionated heparin >15,000 U/day within 8 hours of study entry or low molecular weight heparin used at any dose higher or more frequent than the recommended dose in the product label for DVT prophylaxis within 12 hours of study entry. (b) Direct thrombin inhibitors, such as argatroban, ximelagatran, melagatran, bivalirudin, lepirudin, or recombinant hirudins within 3 days of study entry. (c) Thrombolytic therapy, such as streptokinase, tPA, rPA, or urokinase (unless used to treat intra-catheter thrombosis) within 3 days of study entry. (d) Warfarin, if used within 7 days of study entry or warfarin-type medications within 5 half-lives of study entry and where the prothrombin time is prolonged beyond the upper limit of normal for the institution. (e) Antiplatelet medications, such as ticlopidine, clopidogrel, or ascetylsalicylic acid (ASA) >650 mg/day or compounds that contain ASA >650 mg/day, within 3 days of study entry. (f) Glycoprotein IIb/IIIa receptor antagonists, such as abciximab or eptifibatide, within 7 days of study entry. (g) Recombinant factor VIIa within 30 days of study entry. (h) Antithrombin infusion of >10,000 units within 12 hours of study entry. (i) Protein C concentrate infusion within 24 hours of study entry. [14] Are not expected to survive 28 days given their preexisting uncorrectable medical condition, for example, patients with, or suspected to have the following conditions: (a) Poorly controlled neoplasms (b) End-stage cardiac disease (c) Cardiac arrest requiring cardiopulmonary resuscitation or with pulseless electrical activity or asystole within the past 30 days (d) End-stage lung disease (e) End-stage liver disease (f) HIV/AIDS with known end-stage processes. Refer to Protocol Attachment EVDP.5 for further guidelines. Are moribund and death is perceived to be imminent. [16] Are not committed to aggressive management of the patient. [17] Have received treatment within the last 30 days with drotrecogin alfa (activated). [18] Have previously completed or withdrawn from this study (F1K-MC-EVDP). [19] Are pregnant or lactating and the milk is to be ingested by the newborn. [20] Fail to give written informed consent or the patient?s legal representative fails to give written informed consent. [21] Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at

Age minimum:
Age maximum:
Gender:
Female: yes
Male: yes

Health Condition(s) or Problem(s) studied

Adults patients with Septic Shock persistently dependent to high dosage of vasopressors
MedDRA version: 9.1 Level: LLT Classification code 10040070 Term: Septic shock

Intervention(s)

Trade Name: Xigris
Pharmaceutical Form: Powder for infusion*
INN or Proposed INN: Drotrecogin alfa (activated)
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 20-
Pharmaceutical form of the placebo: Powder for infusion*
Route of administration of the placebo: Intravenous use

Trade Name: Xigris
Pharmaceutical Form: Powder for infusion*
INN or Proposed INN: Drotrecogin alfa (activated)
Concentration unit: mg milligram(s)
Concentration type: equal
Concentration number: 5-
Pharmaceutical form of the placebo: Powder for infusion*
Route of administration of the placebo: Intravenous use

Primary Outcome(s)

Main Objective: The primary objective of this study is to demonstrate that treatment with drotrecogin alfa (activated) 24 mcg/kg/h administered as an intravenous infusion for 96 hours reduces 28-day all-cause mortality in adult patients with septic shock compared with placebo.

Primary end point(s): The primary efficacy measure is 28-day all-cause mortality. The 28-day time point is defined at 672 hours from randomization. All patients will be classified as either ?alive at Study Day 28? or, if dead, ?dead at Study Day 28.?

Secondary Objective: The secondary objectives of this study are as follows: To demonstrate that treatment with drotrecogin alfa (activated) reduces 28-day all-cause mortality in adult patients with septic shock and severe protein C deficiency (baseline protein C level less than or equal to half the lower limit of normal) compared with placebo. To demonstrate that treatment with drotrecogin alfa (activated) improves cardiovascular, respiratory, and renal organ function compared with placebo. To demonstrate that treatment with drotrecogin alfa (activated) reduces 90-day and 180-day all-cause mortality in adult patients with septic shock compared with placebo. To demonstrate that patients treated with drotrecogin alfa (activated) have a similar quality of life compared with patients treated with placebo. To demonstrate that drotrecogin alfa (activated) has an acceptable safety profile in this patient population.

Secondary ID(s)

2007-005441-38-DE

F1K-MC-EVDP